Epidiolex

View All

Epileptic Encephalopathy
Epidiolex vs Fintepla: Fight in Rare Epilepsies

Epidiolex (Jazz Pharma) and Fintepla (Zogenix - Acquired by UCB) are locking horns in the rare developmental and epileptic encephalopathies (DEE) market with Epidiolex currently leading in terms of sale. Epidiolex has clocked over USD 650 million in sales and on the other hand Fintepla is far behind at just USD 74....

Find More

Epilepsy Market
Ever-evolving Market Dynamics of Epilepsy – a silver lining!

Potential and growth of the current market The major drawback of the current antiepileptic drugs (AEDs) is their modest efficacy even at best; therefore, many patients require as many as four concurrent AEDs and contend with their host of side effects. The epilepsy market has witnessed several approvals in the l...

Find More

MEDICAL MARIJUANA
What can be the scope of Medical Marijuana?

What exactly is Marijuana? In a layman language, Marijuana is the dried buds and leaves of a plant Cannabis sativa favored in warm, wild tropical climates. Earning names like pot, ganja, weed, hemp, hash, etc. it contains around 104 active cannabinoids (CBD). What they do is, they mimic the signal producing che...

Find More

merck
The Business Cocktail

Biohaven buys PRV from GW Pharmaceuticals for USD 105 million GW Pharmaceuticals has announced its decision to sell its rare pediatric disease priority review voucher (PRV) to Biohaven Pharmaceuticals. The voucher was issued under U.S. Food and Drug Administration programme to accelerate speedy recovery of rare ...

Find More

The Snippet: The Success of Cannabidiol

GW Pharmaceuticals, a UK based company, believes in growing its own cannabis plants, search for its ingredients and then come up with medicines that help the company in taking one more step towards approval of Epidiolex, as seen in the announcement of positive phase 3 trial results earlier this week. The drug is fo...

Find More